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Abstract: 
Herbal treatments have a long standing tradition for a range of gastrointestinal conditions. In 
contrast, the scientific evidence for the use of herbal preparations is  mixed.  Available 
studies  are plagued by methodological limitations. For functional gastrointestinal disorders 
there is evidence for the use of some well characterized preparations.   In inflammatory 
bowel disease (IBD)  there are limited placebo controlled trials, other  studies use active 
controls with suboptimal doses of the comparators.  
Aside from patchy evidence supporting the use of herbal medicines, it is also of  importance 
to consider that plants and plant extracts contain constituents that may vary depending upon 
environmental conditions during growth. Variable environmental conditions may affect the 
composition and the concentration of the active ingredients. In addition, most herbs provide 
a variable plethora of chemical families with medicinal utility. While these ingredients might 
be of benefit, the concentration and dose of these constituents needs to be closely 
monitored. Nevertheless, many herbal preparations are marketed without evidence for 
stringent adherence to good manufacturing practice (GMP) guidelines. Thus physicians and 
regulators should be very cautious with the use of these remedies. Appropriate scientific 
evidence for the claimed clinical benefits should become mandatory. In addition, the 
standards for production and safety monitoring should comply with established standards for 
chemically defined products. With these processes in mind the full value of herbal remedies 
may come to light particularly as the bioactive compounds present in these preparations 
become recognized. 
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INTRODUCTION 
Herbal remedies are widely used for a variety of gastrointestinal and non gastrointestinal 
disorders. This is reflected by a growing number of publications in this field (Figure 1). A 
recent Cochrane review reported the prevalence of complementary and alternative medicine 
(CAM) usage for countries in the European Community ranges between 0.3 and 86%.1 
Dissatisfaction with conventional therapies appeared to be the most common reason for 
CAM use.1  
A survey in patients with inflammatory bowel disease (IBD) conducted in Italy observed that 
out of a cohort of 705 patients, 126 had used herbal or complementary therapies2.  The 
majority of these patients did not experience an improvement of symptoms as the result of 
the alternative therapies. A Canadian study3  involving 150 IBD patients reported use of 
CAM therapies by 60% of patients. This included 31% relying on exercise, diet, and prayer; 
this latter group was more likely to be older and female.  However it is noteworthy that 
complementary treatments were predominantly used for symptoms such as pain/cramps 
(64%), diarrhea (60%), and gas/bloating (21%). Those using alternative therapies were not 
characterised by more intense health care utilisation, but had experienced insufficient 
symptom relief utilising chemically defined therapies. Comparing use in various countries, it 
appears that use was greater among North American patients than European patients.4 
History of herbs and disease 
Herbal medicine can be considered to be part of the oldest form of healthcare and herbal 
treatments have been used by all cultures throughout history. The medicinal use of plants 
has developed through observation and by trial and error. Herbals contain a variety of 
chemical substances that act upon the body. Many drugs commonly used today are of 
herbal origin. Interestingly the physician/scientist credited with bringing digitalis into 
mainstream medicine is William Withering who observed that digitalis from the foxglove plant 
was used by herbalists for the treatment of dropsy and heart disease. 5 Even the newer 
antimalarial drugs were developed from the discovery and isolation of artemisinin from the 
Artemisia annua plant which has been systematically used in China for almost 2000 years6. 
While knowledge about herbal therapies was initially passed by word-of-mouth this 
knowledge was first documented in  1200 BC during the late Shang dynasty7.   
 
The effects of herbal medicine for a variety of conditions was used and studied in the middle 
ages by benectine monks (i.e.  Codex Bambergensis Medicinalis).8 Other famous work was 
done by Benedictine abbott Walafrid Strabo (Liber de Cultura hortum) published long before 
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print was invented.9 A similar collection of information  is the Speyer Herbal book which is 
believed to be authored by Hildegrad von Bingen.10 
 
Although many flowers and aromatic plants were grown for decorative purposes, other 
plants such as rosemary, aniseed, caraway, cumin, coriander, fennel laurel and mustard 
were cultivated in the herbal gardens of the monasteries and were used in the kitchens or 
pharmacies of these monasteries. It is interesting to note that the School of Medicine at 
Salerno in Southern Italy was in close contact with the nearby monastery of Monte Cassino.  
At that time the ‘Antidotarium Nicolai Salernitani’, written about 1100 was a remarkable 
collection of herbal recipes that were used by physicians. In the first version it contained 60 
formulae. 11 
The German Benedictine nun Saint Hildegard of Bingen (1089-1179) authored two volumes 
of medical books, namely ‘Liber Simplicis Medicinae’ (The Book of Simple Medicine) and 
‘Liber Composite Medicinae’ (The Book of Compound Medicine). These books contained 
detailed observations and recommendations on the effects of herbals and their therapeutic 
effects. This knowledge was acquired in part through experience in the gardens of nun’s 
convents. St. Hildegarde herself was a member and later mother superior of the 
Disibodenberg community near Bingen in the Rhine Valley.12 
Challenges with herbal medicines 
It is evident that while experience and systematic observation had provided the platform to 
formulate treatment recommendations using herbals, it must be recognised that the 
underlying pathophysiologic concepts or pharmacologic modes of action were not known. 
Modern evidence based medicine targets well defined disease mechanisms with highly 
standardized synthetic medicines. To a large degree this has replaced herbal medicines. 
The advantages are evident. Optimal doses of pharmacological active ingredients can be 
administered, potential ingredients of herbal mixtures that may cause adverse events are 
eliminated and the activity or concentration (dose) of the treatment is not influenced by 
metereological variation (e.g. sun exposure), the seasons, or the physical composition of the 
soil in which plants are grown.      
On the other hand, in many Asian and African countries, large proportions of the population 
depend on traditional medicine for primary health care. Interestingly, herbal medicines are 
the most lucrative form of traditional medicine, generating billions of dollars in revenue and 
are used to treat a large variety of conditions.13However in context the medical costs for 
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ulcerative colitis alone in the US in 1990 were estimated to be $0.4-0.6 billion and this does 
not inlcude the more expensive biological therapies that are commonly used today. 14While 
herbal medicines have a long tradition, there are significant challenges to overcome when 
they are used as routine treatments. In the evidence based medicine environment, it is at 
least desirable that the treatment is based upon accepted pathophysiologic concepts. 
However, it must be acknowledged that for some conditions pathophysiologic concepts are 
not well established for each individual that receives treatment.  The other challenge is that 
clinical efficacy should be established. Thus properly designed, randomized placebo 
controlled trials need to support the assumption that the treatment actually improves the 
disease or the symptom that is targeted.  
Another key issue is the quality of the manufacturing process and standardisation of herbal 
medicines. These medicines are derived from plants that are grown in soils of variable 
quality and under diverse environmental influences, (temperature, hours of sunshine, 
humidity), that can have substantial effects on the active ingredients. In addition, variations 
in species of plants also needs to be considered. While the monks and nuns attempted to 
standardize environmental conditions for their plants by using protected monastery gardens 
in which to grow their herbs, this is not a solution for the industrial production of large 
quantities of herbal medicines. Good Agricultural Practices (GAP) recommend production 
and farm level approaches to ensure the raw materials used for herbal preparations are safe 
and without contamination or huge fluctuations in active ingredients, are  not easy to 
achieve. For this reason, long standing supply arrangements between farmers producing 
herbals and pharmaceutical companies producing herbal medicines frequently occur. With 
these arrangements manufacturers aim to standardize the quality of the plant raw material 
used in  production. This is clearly a different approach compared to the purchase of raw 
materials originating from a variety of  producers from different geographic regions with 
potentially differing concentrations of active ingredients. 
Plants and plant extract contain constituents synthesized during plant growth under various 
environmental stresses, providing a plethora of chemical families with medicinal utility.  Thus 
another challenge is the standardization of extraction of the active ingredients. While there 
are established standards such as the European Pharmacopoeia (Ph Eur), in-house 
specifications that are based upon extract constituents and chemical properties may 
influence the characteristics and properties of a given herbal preparation. Thus, besides the  
origin, production and harvesting conditions of the plant, there are multiple factors that 
potentially influence the quality and ultimately the efficacy of a herbal medicine. There are 
sometimes concerns of bioequivalence of chemically defined drugs from different 
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manufacturers or sources, but the challenge of bioequivalence is even more important for 
herbal medicines. 
 
Standardized extraction conditions may be  applied and relevant quality parameters 
monitored such as drug-to-extract ratio (DER), the quality of the herbal drug (water content, 
content of extractable substances), the extraction solvent (concentration, time flow) and the 
procedure conditions (time, temperature, pressure). These  all play a part in defining product 
quality.15-18 These parameters need to be well defined and standardized to ensure quality 
standards of the product.  
 
While chemically defined treatments target defined pathophysiologies, not all conditions and 
diseases have as yet comprehensively defined pathophysiological mechanisms that can be 
cured with a short term pharmacologic intervention. In gastroenterology, functional 
gastrointestinal disorders fit into this category.  
Complementary and Alternative Medicine 
CAM is widely used in the general population and in patients with chronic disorders such as 
inflammatory bowel disease.4,19 On the other hand, the efficacy of chemically defined drugs 
is limited in the treatment of patients with functional gastrointestinal disorders.  As a 
consequence there is an unmet treatment need for treatment to manage patients with 
irritable bowel syndrome (IBS) and functional dyspepsia, and for many years herbal 
medications have been used in many countries for this purpose. A google search of the term 
“herbal treatment for dyspepsia” revealed more than 1 millions hits. This compared to 1.7 
million hits for  “PPI treatment for reflux” . There has been a steady increase in publications 
for complementary and alternative and herbal medicine over the past 30 years (Figure 1). 
 
Herbal treatments for functional gastrointestinal disorders 
There are a number of clinical trials focussing on the effects of herbal medicines in patients 
with functional dyspepsia  20-34 (Table 2) and IBS  35-37,40-41 (table 3). Most studies suggest 
efficacy of these herbal preparations. However, not all outcome parameters were assessed 
utilising validated instruments and blinding of herbal preparations is a critical problem of 
virtually all herbal trials. However it is important to note that in a matched-pair study a higher 
quality of placebo-controlled trials was shown for herbal medicines compared with 
conventional medicine. 38  
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Overall, compared to chemically defined treatments, the number of trials focusing on 
functional dyspepsia and IBS is limited. One meta-analysis assessed the evidence for 
xiaoyao san (MXS) for treating functional dyspepsia (FD). The total effective rate of symptom 
improvement in this study for MXS ranged from 82.6% to 93.7%. Furthermore symptoms 
were reduced by a combination of MXS and prokinetic drugs compared to prokinetic drugs 
alone (odds ratio 4.32, 95% CI 2.64 to 7.08). However, there was evidence for publication 
bias and methodological flaws, which may have amplified the therapeutic benefit of MXS.  39 
Another  study assessed a  fixed combination of peppermint oil (90 mg) and caraway oil (50 
mg) in a cohort of less than 50 patients with functional dyspepsia and found that this resulted 
in significant improvement of symptoms compared to placebo. 31Placebo-controlled trials 
(Table 2) have reported significant improvement of symptoms in functional dyspepsia during 
treatment with specific herbal preparations 20-24, 26-28,30-33  One study showed a significant 
improvement in FD symptoms with chios mastic gum over placebo.25  Another study showed 
improvement in FD and psychological symptoms with xinwei decoction compared with 
domperidone and placebo.23 Artichoke leaf extract has been shown to improve FD 
symptoms and quality of life. 33 The results from studies in IBS (Table 2) however have been 
more mixed. 35-37 
A meta-analysis has also shown that supplementation of peppermint oil, in addition to 
pharmacological standard treatments, was of benefit to both constipation predominant IBS 
and diarrhea predominant IBS patients.42  Another study showed a significant long lasting 
improvement of Chinese herbal medicine (standardized and individualised) compared to 
placebo in IBS. 36  However one study utilising traditional Chinese medicine extracts from 11 
herbs failed to find a global improvement in symptoms in patients with diarrhea predominant 
IBS over placebo. 41It could be that the use of extracts rather than raw herbs may account 
for this descrepancy with some unknown yet important component being lost in the water 
extraction process. Also the placebo in this study did contain a very small amount of lactose. 
Others have found no therapeutic benefit of curcuma xanthorriza or fumaria officinalis over 
placebo in the treatment of IBS related pain or distension.40  
Major problems of alternative medicines are related to a lack of standardization of the 
compounds, the inclusion of multiple potentially active extracts, and lack of knowledge about 
their long-term safety and precise mechanisms of action.43  Use of herbal medicine should 
be restricted to compounds that have been properly tested according to Good Clinical 
Practice (GCP) guidelines and are produced according to GMP standards.  Several clinical 
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trials are available for the herbal preparation STW5. This preparation contains extracts from 
bitter candy tuft, chamomile flower, peppermint leaves, caraway fruit, licorice root, lemon 
balm leaves, angelica root, celandine herbs, milk thistle fruit and is produced according to 
GMP standards and was tested in several clinical trials and has been shown to be superior 
to placebo in the treatment of functional dyspepsia.44 The use of STW5 has also been found 
to be effective over placebo in the treatment of IBS symptoms. 35 
Mechanistic studies 
While some data in relation to clinical efficacy and some in vitro studies exist, very little work 
has been done to characterize effects of herbal medicines in humans. As shown in table 1 
one clinical study 45 observed an increased in the motility index of antral pressure waves in 
the first 60 minutes after administration of STW5. However, retention of liquids in the 
stomach was slightly increased but there was no effect on gastric emptying of solids or 
intragastric distribution. Other effects may relate to a modulation of the gastrointestinal 
microbiome. Although  this has not yet been systematically studied, aloe vera appears to 
promote the growth of Lactobacilli such as L. acidophilus, L. plantarum and L. casei 46  
 
Herbal treatments for inflammatory bowel disease (IBD) 
Many herbal preparations have immunomodulatory effects. 47-57 Thus it appears reasonable 
to trial herbal medications in patients with IBD. On the other hand, good, large clinical trials 
testing the effects of herbal therapy in IBD are widely lacking. In a very small randomised 
placebo controlled study in patients with mild to moderate active ulcerative colitis, 
sigmoidoscopic scores and laboratory variables showed no significant differences between 
aloe vera and placebo. However, clinical remission, or improvement and response of 
symptoms occurred in 30%, 37% and 47%, of 30 patients randomised to receive aloe vera 
compared to 7% (P<0.1),  7% ([P<0.06) and 14% (P < 0.05), of 14 patients taking placebo.58 
Curmarin is a member of the ginger family (Zingiberaceae). The curcuminoids are natural 
phenols that are responsible for the yellow color of turmeric. A recent Cochrane analysis 
reviewed the existing analyses and found that only one trial fulfilled the entry criteria. 59In the 
curcumin group 22% relapsed compared to 32% in the control group (P = 0.31). However it 
was noted that the endoscopic appearance of the mucosa at six months was significantly 
better in the curcumin group than in the control group. The authors of the Cochrane review 
concluded that curcumin may be a safe and effective therapy for maintenance of remission, 
but more data are required.  
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A herbal treatment with myrrh, dry extract of chamomile flowers and coffee charcoal has 
anti-inflammatory and antidiarrheal potential. In a randomised trial with a study population of 
less than 100, no inferiority with regard to the ability to maintain remission for this mixed 
preparation compared to the gold standard therapy mesalazine, was found. 60   The study 
showed that 22 patients treated with mesalizine experienced a relapse compared to 25 
treated with the herbal preparation. It needs to be noted that the gain over placebo is usually 
less than 20% with mesalazine 61  and typical studies recruited several hundred patients to 
demonstrate a significant difference. In addition, well controlled studies demonstrate that 
higher doses (e.g. mesalazine 3.0 g OD are superior to the 0.5 g tid) are significantly better 
compared to 3 x 0.5 tid.62 While traditional medicines such as oral 5-aminosalicylic acid 
drugs, oral corticosteroids and particularly the recent emergence of biological therapies have 
been found to be effective in inducing remission in IBD patients, these treatments have also 
been associated with varying cost effectiveness outcomes.63  Thus, future research studies 
should also seek to compare the cost effectivness of herbal preparations to the  newer 
chemically defined approaches for the treatment of IBD. 
Adverse events related to herbal medicines 
It needs to be noted that there are numerous case reports on adverse events related to 
herbal medicines. 64-67 These adverse events range from allergic reactions, 68-69 
gastrointestinal side effects, 70 acute hepatitis 71 or other serious adverse events including 
Stevens-Johnson syndrome, anaphylactic shock and exfoliative dermatitis including 
reactions that may necessitate hospital admissions. 72 There have also been reports of 
hepatotoxicity. A critical review by Teschke et al. 73 revealed that many different herbs and 
herbal products have been implicated to cause toxic liver disease, however significant issues 
with the quality of these studies renders it difficult to determine whether the herbs were 
actually causal.  Unlike other medications most herbal preparations are not regulated by the 
same legal and regulatory framework that applies for other medications and as such there is 
no mandatory reporting of adverse events. As a consequence only a very small proportion of 
adverse events might be recognised. Indeed, in a study conducted in the UK, more than 500 
herbalists of the UK Register of Chinese Herbal Medicine were invited to participate in a 
study where  each were to approach 10 consecutive patients and recruit them for 
participation. After informed consent, patients had to complete a baseline survey. After 4 
weeks patients received a follow-up questionnaire which assessed adverse events 
potentially related to the Chinese herbal medicine during the 4 week treatment. Only 71 out 
of 700 herbalists agreed to participate and in total 194 patients returned baseline 
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questionnaires. 144 (74%) patients completed the 4-week follow-up questionnaires. 20 of the 
144 patients (14%) reported 32 adverse events associated with Chinese herbal medicine 
over the 4-week period. However, in this survey no serious adverse events were reported. 74   
It is important to note that  the available published information strongly suggests that safety 
of herbal medicines cannot be taken for granted. They should be regulated in a similar way 
as chemically defined over-the-counter drugs.  
Conclusions 
Herbal medicines are widely used, predominately as over the counter preparations. The 
main driver for the use of herbal and complementary medicines is the unmet need of 
patients. This is in particular evident for functional gastrointestinal disorders. While there is 
relatively solid evidence for some herbal preparations, many trials conducted in this field 
have substantial methodological deficiencies such as sample sizes, blinding and 
assessment of outcome parameters.  
On the other hand it must be acknowledged that most preparations tested are not patentable 
drugs and therefore the financial return of investments into clinical trials utilising widely used 
herbal preparations is very unlikely. As a consequence there is limited investment of 
producer and distributors of herbal medicines to further explore efficacy and safety of herbal 
medicines. It must also be acknowledged that the effect of herbal medicines  may not simply 
result from  the combination of various known active ingredients, but the effect of as yet 
unrecognised biologically active components of a particular herbal preparation. Due to the 
complexity of chemical components and potential actions, a comprehensive understanding 
of herbal drugs remains a challenge. To address this, research in this field requires a 
comprehensive systems approach in order to identify  active ingredients and their targets. 81 
The widespread notion that herbal therapies are non-effective but safe might not be correct. 
Herbal medicines contain multiple active ingredients that have the potential to be beneficial 
(or harmful) for a number of medical conditions. At the same time herbal medicines have the 
potential of significant adverse effects. This might be particularly relevant if herbal 
preparations are not produced under closely monitored conditions and post marketing safety 
surveillance conducted in a rigorous manner that is well established for chemically defined 
medications. Thus, therapies utilising herbal medicines should consider risk benefit 
analysis and it may be a matter of time for some herbal treatments until more evidence 
for their use is available. 
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Figure 1: There has been a steady increase in publications for complementary and 
alternative and herbal medicine over the past 30 years Publications with the key words 
“Complementary Alternative Medicine” or ”Herbal” were used and compared with the term 
“Evidence Based Medicine”.  
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Table 1: In vivo effects of plant extracts on gastrointestinal motor and secretory function 
Plant Effects gastrointestinal 
on motility 
Secretory 
effects 
Other properties Clinical trials References 
Angelica 
( Angelica 
Archangelica) 
 
Dose-dependent 
enhancement of  
gastrointestinal tract 
motility in mice when 
compared with the 
negative control.77 
 Cytoprotective 
effect against 
cyclophosphamide 
of stem cells and 
intestinal tissues 
77 
 
 76-77 
Artichoke 
(Cynara 
scolymus) 
Spasmolytic effect 78 
 
Choleretic and 
anti-cholestatic 
effects as well as 
inhibiting actions 
on cholesterol 
biosynthesis and 
LDL oxidation 79 
Potential prebiotic 
effect 80 
 
 78-80 
Bitter candy tuft 
(Iberis amara) 
 Stimulatory effect on 
smooth muscles of the 
stomach and small 
intestine 87-82 
Acid secretion 
and  leucotriene-
concentration, 
reduced 83 
Dose-dependent 
antiulcerogenic 
effect 
(indomethacin-
induced ulcer). 
Acid secretion and  
leucotriene-
concentration, 
reduced while  
prostaglandin E2 
content, 
increased. 83  
As component of 
STW5 29 
29, 81-83 
Caraway In humans significant   In placebo controlled 84-85 
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(Carum carvi) reductions of contraction 
antral and intestinal 
amplitudes 84 
trial in combination 
with peppermint oil 
improvement of 
symptoms in 
functional dyspepsia 
85
 
Celandine 
(Chelidonium 
majus) 
  Anti-infective 
properties 86 
 86 
Chamonmile 
(Chamomilla 
recutita) 
Matricariarecutita 
Antispasmodic effect due 
to an inhibitory effect on 
Ca(2+) influx through the 
membrane of jejunal 
smooth muscle cells. 87 
 Antidepressive 
and anxiolytic 
effects. 88 
 87-88 
Lemon balm 
(Melissa 
officinalis) 
  
Anxiolytic effects89 
Cytotoxicity 
assays showed a 
significant 
protection of a 10 
mug/ml dose of 
Melissa against 
hypoxia in 
cultured neurons 
90
 
Melissa extract 
demonstrated a 
high virucidal 
activity against 
herpes simplex 91 
 89-92 
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M. officinalis 
aqueous extract 
possesses potent 
antioxidative 
properties 92 
      
Peppermint oil 
  
(Mentha 
x piperita) 
 
Inhibition of gastric 
motility index 93 
Inhibition of duodenal 
motility 94  
Peppermint oil improves 
the manometric features 
of diffuse esophageal 
spasm. No effect on LES 
95
 
   93-95 
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Table 2: Clinical trials in functional dyspepsia (FD)  utilising herbal medicines 
Author Disease Treatment Study 
design 
End point Sample size Sign.  
Zhang et al 
20
 
Functional 
dyspepsia 
(FD) of 
Spleen-
deficiency and 
qi-stagnation 
syndrome 
Chinese herbal 
medicine 
(CHM) 
Gastrosis No.1 
multi-center, 
double-blind, 
placebo-
controlled 
Symptom 
score, after 4 
and 8 weeks 
162, 2:1 
randomization 
P<0.01 
Zhao et al 
21
 
Functional 
dyspepsia 
cold and heat 
in complexity 
syndrome 
Chinese herbal 
medicine Ban 
xia xie xin 
decoction 
 
randomized, 
double-blind, 
placebo-
controlled 
multicenter 
trial  
Dyspepsia 
symptom 
score 
101, 2:1 
randomisation 
P<0.01 
Zhang 22 FD of spleen-
deficiency and 
qi-stagnation 
syndrome 
Chinese herbal 
medicine 
LiuJunZi 
decoction 
randomized, 
double-blind, 
placebo-
controlled 
multicenter 
trial 
Primary: 
Dyspepsia 
symptom 
scale, 2,4,8 
weeks, 
Secondary: 
emptying of 
radiopaque 
barium 
markers 
160, 2:1 
randomization 
Symptoms: (P < 
0.01)., 
Gastric emptying: (P 
< 0.05). 
Arai et al 23 Functional 
dyspepsia 
Rikkunshito vs. 
domperidone 
paralleled, 
randomized 
controlled 
trial 
Primary: 
Dyspepsia 
symptom 
rating scale 
(GSRS),  4 
27, 1:1 
randomization 
Significant 
improvement of 
symptoms in both 
groups, correlation 
of symptom 
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weeks, 
Secondary:  
of acylated 
ghrelin (AG) 
 
improvement with 
change of AG 
Wu et al 24  FD of spleen-
deficiency and 
qi-stagnation 
syndrome. 
 
Two kinds of 
Zhizhu pills, 
one contains 
immature 
orange fruit of 
Citrus 
aurantium 
L.(IFCA) and 
the other 
contains that 
of Citrus 
sinensis 
Osbeck 
randomized, 
group 
sequential, 
double-
blinded, 
multicenter 
trial 
Symptom 
score 
163, cross over, 
randomised 
Zhizhu pills 
containing IFCA 
significantly superior 
Dabos et al 
25
  
FD, Rome II 
criteria 
Chios mastic 
gum 
Randomised 
parallel 
group, 
placebo 
controlled 
Symptom 
score and 
patients 
global 
assessment 
148, 1:1 
randomisation 
Marked in 77% of 
patients with active 
compared to 40% 
with placebo, p<0.05 
Braden B et 
al 26 
FD Rome II Stw5 vs. 
placebo 
Randomized, 
double blind 
placebo 
controlled 
Symptoms 
and gastric 
emptying 
103, 1:1 
randomisation 
Improvement of 
symptom score 
(GIS) P<0.08 
vs.placebo, 
Larger proportion of 
patients responder 
with Stw5 (p<0.05) 
Van Armin 
et al 27 
FD Rome II STW5 vs 
Placebo 
Randomized, 
double blind 
placebo 
controlled 
Symptoms 
(GIS) 
315, 1:1 
randomization 
Active therapy 
significantly better 
(p<0.05) after 8 
weeks 
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Zhao & 
Gan 28 
Functional 
dyspepsia 
accompanied 
with 
depression 
and anxiety 
Xinwei 
Decoction vs. 
domperidone 
vs. placebo 
Parallel 
group design 
FD 
symptoms 
and anxiety & 
depression 
scale (HADS) 
73, 1:1:1 Dyspepsia 
symptoms: Xinwei 
Decoction vs 
placebo and 
domperidone 
P<0.05,  
Freise et al 
32
 
Functional 
dyspepsia and 
IBS 
enteric coated 
capsule 
containing 90 
mg peppermint 
oil and 50 mg 
caraway oil vs 
enteric soluble 
formulation 
containing 36 
mg peppermint 
oil and 20 mg 
caraway oil 
was used as 
the reference 
Parallel 
group design 
Symptom 
improvement 
213, 1:1 
randomisation 
Lower pain 
frequency in the 
enteric coated high 
dose group. 
Holtmann 
et al 33 
Functional 
dyspepsia, 
Rome II 
artichoke leaf 
extract vs 
placebo 
Randomized, 
double blind, 
paralleled 
group 
Quality of life 
(QOL) 
assessed by 
the Nepean 
Dyspepsia 
Index (NDI). 
244 Active significantly 
better (p<0.05 ) 
Madisch et 
al 29  
Functional 
dyspepsia 
Rome II 
STW5 vs 
placebo 
Randomised 
double blind 
parallel 
group,  
GIS score 120 patients 4 
treatments 
groups with 
cross over after 
4 weeks 
STW5 significantly 
(p<0.05) superior to 
placebo 
Holtmann 
et al 34 
Functional 
dyspepsia 
fixed 
peppermint 
oil/caraway oil 
Randomised 
double blind 
parallel 
Symptom 
score 
120 patients Peppermint/caraway 
significantly (p<0.05) 
superior as 
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vs placebo group, compared to 
placebo 
Rösch et al 
30
 
Functional 
dyspepsia 
STW5 vs 
cisapride 
Randomised 
double blind 
GIS score 137 patients No significant 
difference 
May et al 31 Non ulcer 
dyspepsia 
fixed 
peppermint 
oil/caraway oil 
vs placebo 
Randomised 
double blind 
change in the 
intensity of 
pain and the 
global clinical 
impression 
45 patients Both endpoint 
significantly 
improved  
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Table 3: Clinical trials in irritable bowel syndrome (IBS)  utilising herbal medicines 
Author Disease Treatment Study 
design 
End point Sample size Sign.  
Madisch et 
al 35  
IBS, Rome II STW 5 (n = 
51), research 
herbal 
preparation 
STW 5-II (n = 
52), bitter 
candytuft 
mono-extract 
(n = 53) or 
placebo (n = 
52). 
Randomised 
double blind 
changes in 
total 
abdominal 
pain and 
irritable 
bowel 
syndrome 
symptom 
scores 
N=207, 1:1:1:1 STW 5 ands 
research preparation 
STW 5-II superior to 
placebo and 
candytuft mono-
extract 
Bensoussa
n et al 36 
IBS Chinese herbal
 medicine 
(standard and 
individualized 
CHM) placebo 
Random 
treatment 
allocation 
Symptom 
improvement 
113, 1:1:1 Significant 
improvement during 
active as compared 
to placebo. 
Individualised 
therapy had long 
lasting effects 
Brinkhaus 
et al  40 
 
IBS Curcuma 
xanthorriza, 
fumaria 
officinalis, 
placebo 
Random 
double blind, 
placebo 
controlled 
Global 
patient rating 
of IBS related 
pain and 
distension 
106 No therapeutic 
benefit over placebo 
for 
IBS pain (P=0.81). 
IBS distension 
P=0.48) 
 
Leung et al 
41 
 
Rome II IBS – 
diarrhea 
predominant 
Traditional 
medical 
extracts – 11 
herbs 
Random 
double blind, 
placebo 
controlled 
Global 
symptom 
assessment 
119 No global 
improvement over 
placebo P=0.38 
Merat et al 
37
 
IBS Colpermin 
(peppermint 
Random 
double blind, 
IBS symptom 
improvement 
90 Abdominal pain 
improvement 
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oil) placebo 
controlled 
(p<0.0001) 
  
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
